Yoshikawa A, Takahashi K, Kishimoto S, Tsuda F, Akahane Y, Naito S, Tanaka T, Yoshizawa H, Yamasaki M, Okamoto H
Japanese Red Cross Blood Center, Saitama-Ken.
J Immunol Methods. 1992 Apr 8;148(1-2):143-50. doi: 10.1016/0022-1759(92)90167-r.
The putative core gene of hepatitis C virus (HCV) was incorporated into a plasmid vector (pCC5-J4), and expressed in Escherichia coli. The product of 180 amino acids (p20c) was purified by gel electrophoresis in the presence of sodium dodecyl sulfate, and used in enzyme-linked immunosorbent assay for antibodies against the putative core protein of HCV (anti-p20c). Anti-p20c was detected in 13 (1.5%) of 873 apparently healthy blood donors. It was detected in 205 (86.5%) of 237 patients with acute or chronic non-A, non-B (NANB) hepatic disease, significantly more frequently (p less than 0.01) than antibodies against the C100-3 protein encoded by nonstructural regions of HCV (anti-C100-3) that was found in 178 (75.1%). Anti-p20c developed in the circulation of a patient with acute NANB hepatitis much earlier than anti-C100-3. HCV RNA was detected by polymerase chain reaction in serum samples from blood donors positive for anti-p20c in high titers, one of which was negative for anti-C100-3. These results indicated that anti-p20c would be useful in complementing anti-C100-3 for the diagnosis of NANB hepatitis and further decreasing the incidence of posttransfusion NANB hepatitis.
将丙型肝炎病毒（HCV）的假定核心基因插入质粒载体（pCC5-J4），并在大肠杆菌中表达。通过十二烷基硫酸钠存在下的凝胶电泳纯化180个氨基酸的产物（p20c），并将其用于检测针对HCV假定核心蛋白的抗体（抗p20c）的酶联免疫吸附测定。在873名表面健康的献血者中，有13名（1.5%）检测到抗p20c。在237例急性或慢性非甲非乙型（NANB）肝病患者中，有205例（86.5%）检测到抗p20c，其检出频率显著高于（p<0.01）针对HCV非结构区编码的C100-3蛋白的抗体（抗C100-3），后者在178例（75.1%）患者中被检测到。抗p20c在急性NANB肝炎患者的循环中出现的时间比抗C100-3早得多。通过聚合酶链反应在抗p20c高滴度阳性的献血者血清样本中检测到HCV RNA，其中一份样本抗C100-3为阴性。这些结果表明，抗p20c在补充抗C100-3用于诊断NANB肝炎以及进一步降低输血后NANB肝炎的发生率方面将是有用的。
